Actively Recruiting
Circulating Tumor DNA in Patients Summoned for Colonoscopy - Liquid Biopsy for Detection, Characterization, Individualized Treatment, and Follow-up of Colorectal Cancer
Led by Helse Nord-Trøndelag HF · Updated on 2025-04-30
3000
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
Sponsors
H
Helse Nord-Trøndelag HF
Lead Sponsor
N
Norwegian University of Science and Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the usefulness of circulating tumor DNA (ctDNA) markers found in blood as a liquid biopsy for diagnosing, predicting outcomes, and monitoring colorectal cancer. The study aims to determine if a panel of ctDNA markers can identify colorectal cancer patients among those scheduled for colonoscopy, and whether the type, number, and level of these markers vary with different colorectal cancer subtypes and their clinical progression. Participants will provide a blood sample and answer a questionnaire at the start of the study. Patients diagnosed with colorectal cancer will be asked to give an additional blood sample during their routine treatment and follow-up visits. This observational study does not involve any experimental treatments but focuses on collecting and analyzing blood samples to assess ctDNA markers. During the study, participants will undergo colonoscopy and be monitored for outcomes such as colorectal cancer, colorectal adenoma, and inflammatory bowel disease within three months after the procedure. Patients with colorectal cancer will be followed for up to five years to track recurrence, treatment response, and survival. The study includes questionnaires and blood tests to gather detailed information and monitor disease progression and response over time.
CONDITIONS
Brief Title
Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 18 years old or older summoned for colonoscopy
- Patient able to understand and sign written informed consent
You will not qualify if you...
- Patient younger than 18 years old
- Patient unable to understand or give written informed consent
- Patient unlikely to comply with the protocol or considered unlikely to complete the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 months
Participants undergo a liquid biopsy based on circulating tumor DNA markers to detect and characterize colorectal cancer and related conditions.
1 to 2 visits depending on colonoscopy scheduling
Duration - Up to 5 years
Participants are followed for up to 5 years to monitor for cancer recurrence, survival, and treatment response after diagnosis or treatment of colorectal cancer.
Periodic visits as determined by clinical follow-up
Trial Site Locations
Total: 1 location
1
Nord-Trøndelag Hospital Trust
Levanger, Norway, N-7600
Actively Recruiting
Research Team
E
Eivor A Laugsand, MD, PhD
S
Siv S Brenne, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here